Merck FDA Thursday, September 4, 2014 0.00 Neutral

FDA Approves KEYTRUDA — Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC secured FDA approval for pembrolizumab injection in 2014, launching the blockbuster Keytruda therapy that has since reshaped the oncology landscape by driving substantial revenue growth and intensifying competition in the checkpoint inhibitor market. This pivotal approval established pembrolizumab as a cornerstone treatment for advanced melanoma and multiple other solid tumors, significantly bolstering Merck’s market position and contributing to the rapid expansion of the immuno-oncology sector.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed